Physician profile
Bryan S Beck
NPI 1720018179
$10,344.02
in general payments reported to CMS, 2019-2025
43 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $290 · 2021: $1,044 · 2022: $1,309 · 2023: $1,540 · 2024: $3,144 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,700 · Travel and Lodging: $1,561 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,699.99 |
| Travel and Lodging | $1,560.70 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,878.81 | 2019-2025 | Aveir, Amplatzer Amulet, Jot Dx |
| Janssen Pharmaceuticals, INC | $973.27 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.29 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $469.26 | 2019-2025 | |
| Edwards Lifesciences Corporation | $378.28 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.23 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $283.74 | 2019-2025 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $244.16 | 2021-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $217.89 | 2022-2025 | Verquvo, Belsomra |
| Medtronic, INC. | $182.31 | 2021-2025 | Corevalve Evolut R |
| United Therapeutics Corporation | $144.80 | 2021-2025 | Tyvaso, Tyvaso |
| Recor Medical INC | $143.62 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $106.37 | 2019-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $106.22 | 2025 | Assure Wcd |
| Novo Nordisk INC | $97.99 | 2025 | Wegovy, Ozempic, Rybelsus |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.